We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » US Guidance Outlines Submissions for Contrast Imaging Indications
US Guidance Outlines Submissions for Contrast Imaging Indications
January 14, 2010
The U.S. Food and Drug Administration (FDA) has issued a final guidance detailing when developers of imaging drugs can add new indications to approved
products without changing associated device labeling and the type of marketing submission they must make to get new indications approved.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor